Novel therapies for open-angle glaucoma
Open-angle glaucoma is a multifactorial optic neuropathy characterized by progressive loss of retinal ganglion cells and their axons. It is an irreversible disease with no established cure. The only currently approved treatment is aimed at lowering intraocular pressure, the most significant risk fac...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Faculty of 1000 Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229725/ https://www.ncbi.nlm.nih.gov/pubmed/25580256 http://dx.doi.org/10.12703/P6-102 |
_version_ | 1782344155115028480 |
---|---|
author | Wentz, Scott M. Kim, Nathaniel J. Wang, Jenny Amireskandari, Annahita Siesky, Brent Harris, Alon |
author_facet | Wentz, Scott M. Kim, Nathaniel J. Wang, Jenny Amireskandari, Annahita Siesky, Brent Harris, Alon |
author_sort | Wentz, Scott M. |
collection | PubMed |
description | Open-angle glaucoma is a multifactorial optic neuropathy characterized by progressive loss of retinal ganglion cells and their axons. It is an irreversible disease with no established cure. The only currently approved treatment is aimed at lowering intraocular pressure, the most significant risk factor known to date. However, it is now clear that there are other risk factors involved in glaucoma's pathophysiology. To achieve future improvements in glaucoma management, new approaches to therapies and novel targets must be developed. Such therapies may include new tissue targets for lowering intraocular pressure, molecules influencing ocular hemodynamics, and treatments providing neuroprotection of retinal ganglion cells. Furthermore, novel drug delivery systems are in development that may improve patient compliance, increase bioavailability, and decrease adverse side effects. |
format | Online Article Text |
id | pubmed-4229725 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Faculty of 1000 Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-42297252015-01-09 Novel therapies for open-angle glaucoma Wentz, Scott M. Kim, Nathaniel J. Wang, Jenny Amireskandari, Annahita Siesky, Brent Harris, Alon F1000Prime Rep Review Article Open-angle glaucoma is a multifactorial optic neuropathy characterized by progressive loss of retinal ganglion cells and their axons. It is an irreversible disease with no established cure. The only currently approved treatment is aimed at lowering intraocular pressure, the most significant risk factor known to date. However, it is now clear that there are other risk factors involved in glaucoma's pathophysiology. To achieve future improvements in glaucoma management, new approaches to therapies and novel targets must be developed. Such therapies may include new tissue targets for lowering intraocular pressure, molecules influencing ocular hemodynamics, and treatments providing neuroprotection of retinal ganglion cells. Furthermore, novel drug delivery systems are in development that may improve patient compliance, increase bioavailability, and decrease adverse side effects. Faculty of 1000 Ltd 2014-11-04 /pmc/articles/PMC4229725/ /pubmed/25580256 http://dx.doi.org/10.12703/P6-102 Text en © 2014 Faculty of 1000 Ltd http://creativecommons.org/licenses/by-nc/3.0/legalcode All F1000Prime Reports articles are distributed under the terms of the Creative Commons Attribution-Non Commercial License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Wentz, Scott M. Kim, Nathaniel J. Wang, Jenny Amireskandari, Annahita Siesky, Brent Harris, Alon Novel therapies for open-angle glaucoma |
title | Novel therapies for open-angle glaucoma |
title_full | Novel therapies for open-angle glaucoma |
title_fullStr | Novel therapies for open-angle glaucoma |
title_full_unstemmed | Novel therapies for open-angle glaucoma |
title_short | Novel therapies for open-angle glaucoma |
title_sort | novel therapies for open-angle glaucoma |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229725/ https://www.ncbi.nlm.nih.gov/pubmed/25580256 http://dx.doi.org/10.12703/P6-102 |
work_keys_str_mv | AT wentzscottm noveltherapiesforopenangleglaucoma AT kimnathanielj noveltherapiesforopenangleglaucoma AT wangjenny noveltherapiesforopenangleglaucoma AT amireskandariannahita noveltherapiesforopenangleglaucoma AT sieskybrent noveltherapiesforopenangleglaucoma AT harrisalon noveltherapiesforopenangleglaucoma |